Scholars Central

Conference abstractPublished 1 Jul 2016

Differential adverse events of TNF blockers versus IL-17 axis blockers in treatment of spondyloarthritis

Authors: Marina N Magrey

Case Western Reserve University, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Availability of biologics, particularly tumor necrosis factor alpha (TNF-Ã?±) inhibitors, has revolutionized the treatment of spondyloarthritis (SpA). The main side effect associated with TNF-Ã?± inhibitors is increased rate of infection. Despite significant concerns about tolerability and adverse events of TNF-Ã?± inhibitors in treatment of SpA, they have stood the test of time with acceptable safety outcomes. However, there is a subset of patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) who fail to respond to TNF-Ã?± inhibitors, lose efficacy over a period of time, or develop serious adverse events, particularly opportunistic infections. Newer therapeutic options have become available for these patients including interleukin-17 (IL-17) axis antagonists. Their safety data is limited to clinical trials only, with no registry data available as yet. There are no large head-to-head comparative trials between TNF-Ã?± inhibitors and IL-17 axis inhibitors. Based on data from clinical trials of relatively limited duration, infection rates are quite similar between these two classes of biologics but there are, as yet, no reports of reactivation of opportunistic infections like tuberculosis with IL-17 axis antagonists. However, pre-screening for tuberculosis and prophylaxis in appropriate candidates is still needed. The current available data have shown no other major discrepancies in the adverse events between TNF-Ã?± inhibitors and IL-17 axis inhibitors. More data is needed to effectively determine the comparative safety of TNF-Ã?± inhibitors versus IL-17 axis antagonists.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Clinical & Experimental Pathology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical & Experimental Pathology
  • SubjectPathology & Lab Medicine
  • BylineArticles whose byline prints “Marina N Magrey”